TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025. Management Commentary“2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengthen our balance sheet. Furthermore, we achieved a 17% increase in net revenue, driven predominantly by expanded pharmaceutical sales volumes and...

CALGARY, Alberta, April 30, 2026 (GLOBE NEWSWIRE) — Black Diamond Group Limited (“Black Diamond”, the “Company” or “we”), (TSX:BDI), a leading provider of space rental and workforce accommodation solutions, today announced its operating and financial results for the three months ended March 31, 2026 (the “Quarter”) compared with the three months ended March 31, 2025 (the “Comparative Quarter”). All financial figures are expressed in Canadian dollars. Key Highlights from the QuarterConsolidated revenue for the Quarter of $130.0 million and Adjusted EBITDA1 for the Quarter of $32.0 million increased 27% and 21%, respectively, from the Comparative Quarter. Consolidated rental revenue for the Quarter of $43.8 million increased 16% from the Comparative Quarter. The Company’s...

Netanya, Israel, April 30, 2026 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices, today has released its consolidated financial results for the full year ended December 31, 2025, together with a strong business update for the beginning of 2026. Nir Klein, Chief Executive Officer of Silynxcom, commented: “In 2025, we acted strategically and proactively to expand the presence and brand awareness of Silynxcom in new markets. We established strategic relationships with new distributors, agents and resellers and significantly strengthened our global channel network. We laid a solid foundation in many countries across Asia and reinforced our existing relationships in additional markets worldwide....

On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. Recent Highlights Completed manufacturing of the first two batches of the CYWC628 drug product in accordance with Food & Drug Administration (FDA) Good Manufacturing Practices (cGMP) for the phase 1/2 clinical trial for the treatment of diabetic foot ulcers (DFUs). Completed site onboarding...

Planegg/Martinsried, Germany, April 30, 2026 – Leo International Precision Health AG (“LIPH” or the “Company”, ticker symbol: LEOW), a holding company building a global integrated AI-driven healthcare ecosystem, today published its consolidated financial results for the financial year 2025. The reporting year marked a transformational phase in the Company’s inception and development, establishing the structural, operational and strategic foundation for its growth strategy. 2025 HighlightsSuccessful listing in the General Standard of the Frankfurt Stock Exchange by means of a reverse takeover of SPOBAG AG establishing LIPH as a publicly listed precision health platform. Acquisition of six majority shareholdings forming the operational foundation of the Group’s integrated precision healthcare ecosystem in December 2025; with current valuation...

Diluted earnings per share (“EPS”) of $0.57 Invested $21 million in water and wastewater utility infrastructure during the three months ended March 31, 2026 Declared $0.36 common stock cash dividendISELIN, N.J., April 30, 2026 (GLOBE NEWSWIRE) — Middlesex Water Company (“Middlesex” or the “Company”) (NASDAQ: MSEX) today announced financial results for the first quarter ended March 31, 2026. “Our first-quarter results reflect disciplined execution across our operations, capital program, and regulatory strategy,” said Nadine Leslie, Chair, President and Chief Executive Officer of Middlesex Water Company. “We remain focused on delivering reliable service, investing strategically for long-term growth, and advancing our MWC 2030 Vision. This performance underscores the strength of our fundamentals and the dedication of our employees...